Customs and Pudong International Airport Customs
jointly proposed selecting some CRO companies in the Zhangjiang High-Tech Park
for trial operation of express clearance, which implements various measures
including "declaration in advance and clearance upon goods arrival",
"archiving system of classification and price review", "assured clearance" and
"24-hour appointed clearance", to establish a new customs clearance model for
CRO companies and achieve a balance between strict supervision and efficient
operation.
The first 3 CRO companies were recommended by Zhangjiang Park to governing
customs after considering various factors such as company reputation, track
record, size, and status. Then they were selected by customs after strict
review and screening regarding the companies' credibility, internal management
system, laboratory qualification and customs clearance record.
At present, customs is gradually putting more effort into the trial
operation. The next step will be expanding the operation within Zhangjiang
Park on the basis of previous experience so that more companies can benefit
from the new measures, and better service can be provided to help the growth
of CRO industry.
"This is really a big step by Chinese customs to support the growth of
Sundia and other CRO companies. We are encouraged by this and many other
measures the Chinese Government put together to help the development of CRO
industry," commented by Dr. Xiaochuan Wang, Sundia's Chairman and CEO.
About Sundia MediTech Company:
Sundia is a leading integrated pharmaceutical contract research
organization (CRO) company based in Shanghai, China. Sundia provides services
to biotech and pharmaceutical companies worldwide, ranging from early hit
screening, biological service, lead optimization, DMPK, candidate preclinical
development, formulation development, API manufacture, and regulatory
submission. For more
'/>"/>
SOURCE Sundia MediTech Company Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Sundias Animal Facility Passed Client and Government Inspection2.
Sundia MediTech in Deloitte Technology Fast 500 Asia Pacific List3.
Sundia MediTech and Xcovery Announce Big Success in Drug Discovery4.
Sundia MediTech Ranked #16 in Deloitte Technology Fast 50 China5.
CEL-SCI Files Patent Application to Support Companys Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses6.
Lytix Biopharma and KAEL-GemVax Announce Joint Clinical Trial to Combine LTX-315 and GV1001 Cancer Immunotherapy7.
NeoStem Signs Agreement with Shanghai Corporation to Develop A Stem Cell Collection and Treatment Network in Shanghai, Taiwan and Other Targeted China Provinces8.
Modigene Shareholders Approve Company Name Change and Other Proposals at Annual Meeting9.
AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer10.
CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement11.
NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS